The Sino Biological R&D team has many years of experience in recombinant protein research and development. Over the years, the team has generated more than 6,000 recombinant proteins currently in stock covering most hot research areas such as immune checkpoints, antibody drug targets, CAR-T cell therapy targets, Fc receptors, influenza viral proteins and cytokines.
Exhibiting properties of high purity and validated bioactivity, Sino Biological recombinant proteins can support your scientific research from biopharmaceutical target discovery, protein structure and function analysis, cell therapy and recombinant enzyme characterization.
SARS-CoV-2 Antigens |
Immune Checkpoint Proteins |
CAR-T Cell Therapy Targets |
|---|---|---|
| Sino Biological Inc. has developed a panel of recombinant antigens for SARS-CoV-2, including the N (nucleocapsid) protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins, Plpro protein. | Covers most hot immune checkpoint proteins including PD-1/ PD-L1 and CTLA-4 approved antibody drugs as well as prospective drug candidates such as TIM-3, CD47, GITR, etc. | Covers many hot cell therapy targets including CA9, EGFR and CD274 approved antibody drugs as well as prospective drug candidates such as CD19, CD33, IL3RA, EPCAM, TNFRSF17, etc. |
Antibody Therapeutic Targets |
Cytokines & Growth Factors |
Fc Receptors |
| Covers many antibody therapeutic targets including PD-1 and CD20 approved antibody drugs as well as prospective candidates such as PD-1, Her2 / ERBB2, EGFR, c-MET, IL6, IL17, TNF-alpha…… | GMP-grade proteins available. Covers the entire cytokine family, including the interleukins, chemokines and TNFs. A special focus is on the biopharmaceutical industry and cell therapy strategies. |
Covers the vast majority of Fc receptors across multiple species. Each receptor is verified for high bioactivity of binding to immunoglobulins. |